Ignite Creation Date:
2024-10-26 @ 3:42 PM
Last Modification Date:
2024-10-26 @ 3:42 PM
Study NCT ID:
NCT06641661
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-10-11
Brief Title:
NPC1L1 Gene Polymorphism and the Efficacy and Safety of Hybutimibe
Sponsor:
None
Organization:
None
Study Overview
Official Title:
The Association Between NPC1L1 Gene Polymorphism and the Efficacy and Safety of Hybutimibe in Highvery High Risk ASCVD Patients
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Significant individual differences may lead to differences in patients responses to drug therapy and lead to an increased incidence of adverse reactions However there are currently very limited data on the genetic variation of the NPC1L1 gene in the Chinese population In view of the important role of NPC1L1 gene polymorphism in cholesterol absorption lipid profile coronary heart disease prevalence and ezetimibe response it is necessary to focus on the allele frequency analysis of NPC1L1 gene polymorphism in the Chinese population and to further explore the therapeutic response of NPC1L1 gene polymorphism and Hybutimibe
With reference to previous domestic and foreign literature reports and HapMap project httphapmapncbinlm nihgovSNP distribution this study selected NPC1L1 gene loci with relatively in-depth clinical research rs2072183 rs4720470 rs2073547 were analyzed The minimum allele frequency MAF of the above loci were all greater than 10 and it has been confirmed that genetic variation exists between different diseases and different races which may affect the lipid profile the risk of coronary heart disease and the response to hybomaib treatment However the variability of rs2072183 in response to Hybutimibe needs to be further verified and the effects of rs4720470 and rs2073547 gene polymorphisms on drug response also need to be targeted In order to further determine the correlation between the distribution of NPC1L1 polymorphism and the efficacy and safety of Hybutimibe we conducted this study to observe the distribution frequency of NPC1L1 gene polymorphisms at rs2072183 rs4720470 and rs2073547 in high-riskextremely high-risk ASCVD patients To explore the correlation between NPC1L1 gene polymorphisms and the efficacy and safety of Hybutimibe combined with moderate-intensity statins in the treatment of high-riskvery high-risk ASCVD patients This is the first time to explore the distribution of NPC1L1 polymorphism in highvery high risk ASCVD population in China which will provide genetic evidence for the correct use of Hybutimibe and moderate intensity statin therapy and provide further evidence-based medical evidence for the distribution of NPC1L1 polymorphism and the efficacy and safety of Hybutimibe
With reference to previous domestic and foreign literature reports and HapMap project httphapmapncbinlm nihgovSNP distribution this study selected NPC1L1 gene loci with relatively in-depth clinical research rs2072183 rs4720470 rs2073547 were analyzed The minimum allele frequency MAF of the above loci were all greater than 10 and it has been confirmed that genetic variation exists between different diseases and different races which may affect the lipid profile the risk of coronary heart disease and the response to hybomaib treatment However the variability of rs2072183 in response to Hybutimibe needs to be further verified and the effects of rs4720470 and rs2073547 gene polymorphisms on drug response also need to be targeted In order to further determine the correlation between the distribution of NPC1L1 polymorphism and the efficacy and safety of Hybutimibe we conducted this study to observe the distribution frequency of NPC1L1 gene polymorphisms at rs2072183 rs4720470 and rs2073547 in high-riskextremely high-risk ASCVD patients To explore the correlation between NPC1L1 gene polymorphisms and the efficacy and safety of Hybutimibe combined with moderate-intensity statins in the treatment of high-riskvery high-risk ASCVD patients This is the first time to explore the distribution of NPC1L1 polymorphism in highvery high risk ASCVD population in China which will provide genetic evidence for the correct use of Hybutimibe and moderate intensity statin therapy and provide further evidence-based medical evidence for the distribution of NPC1L1 polymorphism and the efficacy and safety of Hybutimibe
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None